Adaptimmune Therapeutics Plc Valeur / Action
Quel est le Valeur / Action de Adaptimmune Therapeutics Plc?
Le Valeur / Action de Adaptimmune Therapeutics Plc est 0.19
Quelle est la définition de Valeur / Action?
La valeur comptable par action est l'actif de la société moins le passif divisé par le nombre d'actions en circulation.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valeur / Action des entreprises dans Health Care secteur sur NASDAQ par rapport à Adaptimmune Therapeutics Plc
Que fait Adaptimmune Therapeutics Plc?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Entreprises avec valeur / action similaire à Adaptimmune Therapeutics Plc
- Red 5 a Valeur / Action de 0.19
- Whispir a Valeur / Action de 0.19
- Thunderbird Resorts a Valeur / Action de 0.19
- Kutcho Copper a Valeur / Action de 0.19
- Tisdale Resources a Valeur / Action de 0.19
- WAC a Valeur / Action de 0.19
- Adaptimmune Therapeutics Plc a Valeur / Action de 0.19
- RENHENG Enterprise a Valeur / Action de 0.19
- Tysan a Valeur / Action de 0.19
- Synairgen plc a Valeur / Action de 0.19
- Ambition a Valeur / Action de 0.19
- Stuhini Exploration a Valeur / Action de 0.19
- Ethos Gold a Valeur / Action de 0.19